S1418

Breast Cancer

S1418: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than or equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes After Neoadjuvant Chemotherapy.

Key Team Members

Principal Investigator

Steven A. Madden, MD

Research Coordinator

Katherine "Kate" Madden

Not Accepting Patients

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

The purpose of this study is to compare the usual approach (no more treatment or additional chemotherapy and radiation therapy after surgery or radiation therapy alone after surgery), with any effects (good or bad) of receiving one year of therapy with the experimental drug pembrolizumab (also called MK-3475) after surgery.